After the turbulent 2016, the H1 report showed that Nexstim is back on track. The company reported sales growth at slightly lower level than our FY expectations, but this was offset by low costs. With the current cash balance and expected revenue, the company has financing until the end of 2018. Patient recruitment in the crucial EFIT trial has accelerated after a slow start and the results are expected in Q2/2018. We believe the trial will be successful, enabling Nexstim to raise capital on fav ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 report: Back on track
After the turbulent 2016, the H1 report showed that Nexstim is back on track. The company reported sales growth at slightly lower level than our FY expectations, but this was offset by low costs. With the current cash balance and expected revenue, the company has financing until the end of 2018. Patient recruitment in the crucial EFIT trial has accelerated after a slow start and the results are expected in Q2/2018. We believe the trial will be successful, enabling Nexstim to raise capital on fav ....